Cost-effectiveness of the Influenza Vaccination
Influenza Vaccine, Cost-Effectiveness, Vaccination
About this trial
This is an interventional prevention trial for Influenza Vaccine focused on measuring High-risk group population, Facility-Based Seasonal Influenza Vaccination, Acceptability, Bangladesh, Cost-Effectiveness, Influenza Vaccine
Eligibility Criteria
Inclusion criteria: Participants who will be visiting study hospitals (outpatients and inpatients only. Not emergency departments) for routine care during the study period. Participants who will be children six months to 8 years or aged more than 60 years or pregnant ( any trimester), or have any chronic disease Participants /parents/caregivers who will be willing to sign the informed consent form. Exclusion criteria: Participants with severe, life-threatening allergies to any ingredient in a flu vaccine (other than egg proteins) Participants having history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of influenza vaccine or to a vaccine component Participants having a history of guillain-barre syndrome less than 6 weeks after a previous dose of influenza vaccine Participants having history of moderate or severe acute illness with or without fever. The vaccine should be given after the acute condition has improved.
Sites / Locations
- Rajshahi Medical College HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Influenza vaccination arm
Control arm ( unvaccination arm)
In the Influenza vaccination hospital, the investigators have run an influenza vaccination campaign before the influenza season, where the vaccines are free to high-risk patients. Posters and leaflets containing information on influenza vaccination have been displayed at the vaccination booths and key hospital locations with information on the vaccination. Eligible patients from inpatients and outpatients of all departments have been offered to take the vaccine during the vaccination campaign. Nurses/ Health Assistants (HA) have provided vaccines after receiving written consent. Vaccination cards have been issued to the participants. All enrolled vaccine recipients are informed about notifying of possible adverse events after immunization (AEFI). To report any AEFI, the investigators are following the existing surveillance channel established by the WHO and the Ministry of Health and Family Welfare(MoHFW), the government of Bangladesh.
In the control hospital, the investigators are also enrolling participants meeting the high-risk group individual criteria. However, no vaccination campaigns are conducted.